Introduction
============

The mobile cardiac telemetry (MCT) system is a small sensor and monitor that patients wear as they go about their daily lives. Whenever cardiac events occur, MCT instantaneously transmits the data to a center for analysis and response, which in turn sends a report along with graphs and trends to the patient's physician for diagnosis and therapy management.[@b1-mder-7-001],[@b2-mder-7-001] Given the convenience of the device and its ability to identify arrhythmia cases that other devices miss (thanks to its superior ability to analyze the morphology of the electrocardiogram \[EKG/ECG\]), the expectation was immediate adoption.[@b3-mder-7-001]

This is not what happened though. Instead, patients continued to use the Holter and Event monitors. Both are small portable devices that the patient wears. The difference between the Holter and the Event is that the Holter records the patient's EKG for 24--48 hours, while the Event records the EKG at certain times only and typically for a 30-day period.

Understandably, several payers responded by asking for hard evidence that indicates that the use of MCT indeed leads to better outcomes before they are to adopt MCT. Several studies were undertaken to explain from a clinical standpoint how MCT leads to better outcomes. Unfortunately, those studies ran into challenges, and could not convincingly demonstrate causality.[@b4-mder-7-001]--[@b7-mder-7-001]

Is MCT not widely adopted just because studies fail to prove its effectiveness?[@b8-mder-7-001] To elucidate the matter, we decided to conduct an observational study that differed from previous ones in one respect. Instead of focusing on explaining causality, this study set out to establish if patients that use MCT indeed have better outcomes. The rationale that links the two was deliberately regarded as out of scope, otherwise this study would be fraught with the same issues that overwhelmed the previous ones.

Materials and methods
=====================

We conducted three analyses to assess the impact of usage of MCT on 1) diagnostic yield of arrhythmia, 2) management of arrhythmia through the use of antiarrhythmic drugs, and 3) cardiovascular costs incurred in the inpatient setting.[@b9-mder-7-001]--[@b11-mder-7-001] [Table 1](#t1-mder-7-001){ref-type="table"} shows the profile of the patients that use MCT, Event, and Holter monitors.

Analysis 1: diagnostic yield
----------------------------

In this analysis, the patient had to meet the following conditions:

1.  used only one cardiac-monitoring device (MCT or Holter or Event monitor)

2.  used the cardiac-monitoring device 12 months after the start of the database and 12 months before the end of the database

3.  had no arrhythmic International Classification of Diseases (ICD-9) diagnosis code prior to using the cardiac-monitoring device.

We then used for each of the three populations: 1) number of patients in the population (none had an arrhythmia diagnosis prior to the use of the cardiac-monitoring device), and 2) number of patients within the previous group that had an arrhythmic ICD-9 diagnosis code after use of the cardiac-monitoring device. We then computed the diagnostic yield as the ratio of 2 to 1.

Analysis 2: antiarrhythmic drug management
------------------------------------------

This analysis is similar to the previous one. The patient had to meet the following conditions:

1.  used only one cardiac-monitoring device (MCT or Holter or Event monitor)

2.  used the cardiac-monitoring device 12 months after the start of the database and 12 months before the end of the database

3.  had no arrhythmic diagnosis ICD-9 code prior to the cardiac monitoring device

4.  \[new\] used no antiarrhythmic drug prior to the cardiac-monitoring device.

We then used for each of the three populations: 1) number of patients in the population (none had an arrhythmia diagnosis or took an antiarrhythmic drug prior to the cardiac-monitoring device), and 2) number of patients within the previous group that took an antiarrhythmic drug after the use of the cardiac-monitoring device. We then computed the antiarrhythmic drug usage as the ratio of 2 to 1.

Analysis 3: cost savings in the hospital setting
------------------------------------------------

The control patients had to meet the following conditions (there were two groups: one for the Holter and the other for the Event monitor):

1.  used only one cardiac-monitoring device (Holter or Event monitor) and did so once

2.  used the Holter or Event monitor 12 months after the start of the database and 12 months before the end of the database.

For pairing to happen, both the test and control patients had to meet the following conditions:

1.  were either younger or older than 65 years, to factor in Medicare

2.  came from the same type of Medicaid state: Medicaid-expansion states (CT and MA), on-track Medicaid states (AZ, DE, ME, MN, NY, PA, WA WI, HI, DC), or Medicaid-challenged states (rest of the US), to factor in dual eligibles whose access to MCT was subject to Medicaid state rules

3.  had the same diagnosis, as defined by the following eight diagnosis groups: acute coronary syndrome, stroke/transient ischemic attack, heart failure, arrhythmia, coronary artery disease, peripheral artery disease, hypertension, and other cardiovascular conditions

4.  used the same drug(s), as defined by the following four drug classes: anti-platelet, antiarrhythmic, anticoagulant, and antihyperlipidemic

5.  used inpatient cardiovascular resources to comparable levels before the cardiac monitor.

We then conducted the following measurements. First, we compared MCT patients with paired-up Holter patients, and second with paired-up Event monitor patients. In both cases, we defined the following: 1) increase in cardiovascular expenses of MCT patients as the difference in cardiovascular costs incurred in the 12 months that followed MCT (post-period) and the cardiovascular costs incurred in the 12 months before MCT (pre-period), 2) the corresponding per-patient difference of the matched control patients to the test patient, 3) the savings due to MCT compared with the other cardiac monitor as the difference between 1 and 2.

We chose a pair-wise test--control approach to allow for the fact that MCT patients may not be a homogeneous group and large differences between patients may occur. Also, we paired each test not with one but with five controls to minimize the vagaries of pairing.

We also conducted additional analyses to refute the following objections:

1.  savings are artificially low because of the way the pairing is done; indeed, costs incurred for the MCT patient are low because the patient is from a low consumer price index (CPI) geography, while the costs incurred for the other cardiac monitoring device are high because the patient is from a high CPI geography

2.  MCT does not lead to any savings, what is happening is simply that costs are still incurred but delayed until the second year following MCT, which the test--control approach fails to pick up on as its postperiod ends before the significant costs are incurred.

In the first case, we reran the analysis by imposing the condition that both test and control patients be from the same geography. The results barely changed, knocking out the CPI argument. In the second case, we reran the analysis, extending the postperiod to 24 months. Once again, the results barely changed, undercutting the basis for the delay argument.

Results
=======

Analysis 1: diagnostic yield
----------------------------

[Table 2](#t2-mder-7-001){ref-type="table"} indicates that 61% of patients that use MCT are diagnosed with arrhythmia subsequent to the use of the monitor. This is to be compared with 23% for those that use an Event monitor and 24% for those that use a Holter monitor. A *Z*-test for the difference between two sample proportions (MCT versus Event) revealed that the proportion of patients diagnosed with arrhythmia was 36% higher when the monitor was MCT instead of an Event (*P*=0.0006). The result was virtually unchanged (35% instead of 36%) when MCT was compared with the Holter (*P*=0.0006).

Analysis 2: antiarrhythmic drug management
------------------------------------------

[Table 3](#t3-mder-7-001){ref-type="table"} indicates that 61% of patients that use MCT are diagnosed with arrhythmia and treated for the first time with an antiarrhythmic drug subsequent to the use of the monitor. This is to be compared with 39% for those that use an Event monitor and 43% for those that use a Holter monitor. A *Z*-test for the difference between two sample proportions (MCT versus Event monitor) revealed that the proportion of patients diagnosed with arrhythmia and treated for the first time with an antiarrhythmic drug was 20% higher when the monitor was MCT instead of an Event (*P*=0.0033). The difference dropped just slightly to 16% when MCT was compared with the Holter (*P*=0.0018).

Analysis 3: cost savings in the hospital setting
------------------------------------------------

[Table 4](#t4-mder-7-001){ref-type="table"} is a summary of the cardiovascular savings (in US\$) incurred in the hospital when the patient used the MCT instead of the Event or Holter monitor when undergoing different types of surgeries. Those savings were registered in the 12 months that followed the use of the cardiac-monitoring device. All the sample sizes were larger than 30 and the *P*-value less than 0.05. The only cases not reported were for patients undergoing a coronary artery bypass graft (CABG) using MCT instead of an Event monitor, and that was because the sample size was only twelve (although savings were very significant US\$150,000, with a *P*-value of 0.0299).

Let us take a closer look at each of the four procedures discussed in [Table 4](#t4-mder-7-001){ref-type="table"}. In the case of ablation, MCT led to savings of US\$35,114 (*P*\<0.0001) in inpatient cardiovascular costs over the 12 months that followed the use of the device compared with the Event monitor and US\$36,115 (*P*\<0.0001) compared with the Holter. ([Table 5](#t5-mder-7-001){ref-type="table"}).

In the case of CABG procedures, MCT led to savings of US\$41,700 (*P*=0.0003) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Holter. ([Table 6](#t6-mder-7-001){ref-type="table"}).

In the case of heart/pericardium procedures, MCT led to savings of US\$17,131 (*P*=0.0281) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Event monitor and US\$8,606 (*P*=0.0003) compared with the Holter. ([Table 7](#t7-mder-7-001){ref-type="table"}).

In the case of valve/septa procedures, MCT led to savings of US\$58,362 (*P*=0.0422) in inpatient cardiovascular costs per patient over the 12 months that followed the use of the device compared with the Event monitor and US\$55,390 (*P*=0.0003) compared with the Holter ([Table 8](#t8-mder-7-001){ref-type="table"}).

Discussion
==========

While there certainly is a good rationale, albeit subtle, as to why use of MCT leads to better patient outcomes, offering an explanation will displace the focus of the discussion to a more controversial area, resulting in the expectation that consensus needs to be reached before any action is to be taken. That is the trap to avoid, so we will refrain from offering any explanation.

Faced with the evidence uncovered here, why would a hospital still be better off not to adopt MCT? For one, it may be the case that MCT generates a significant number of false positives, which the Holter or Event monitors do not, leading the hospital to incur unnecessary treatment costs. But that concern has no merit, as MCT uses a morphology-based diagnosis algorithm that only reports problems that are present in the EKG. Besides, the costs of the MCT, Holter, and Event monitors are very comparable and very small in the larger scheme of things. For another, the hospital may not be convinced of the rationale that underpins the usage of MCT and better patient outcomes. But is that in the best interest of the patients?

Conclusion
==========

Our findings can be summed up as follows: use of MCT instead of an Event or a Holter monitor leads to better outcomes regarding diagnostic yield, management of arrhythmia through the use of antiarrhythmic drugs, and cost savings in the hospital for ablation, CABG, heart/pericardium, and valve/septa procedures.

In the unlikely event that MCT does not offer the benefits discussed, adopting MCT in lieu of Holter or Event monitors will not make the hospital worse off. But if, as we presented, MCT does offer the benefits discussed, then adopting MCT is clearly the superior choice. It is then clear that the optimal decision for the hospital is unambiguous: adopt MCT without any further delay.
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###### 

Demographic information of patients using MCT, Event, and Holter monitors

  -----------------------------------------------------------------------
  Sex: age                  Midwest   Northeast   South   West    Total
  ------------------------- --------- ----------- ------- ------- -------
  Females:\                 0.7%      0.4%        1.1%    0.4%    2.5%
  \<40 years                                                      

  Males:\                   2.2%      1.1%        4.4%    1.2%    8.9%
  \<40 years                                                      

  Females:\                 4.6%      2.1%        7.3%    2.2%    16.1%
  \<40 years 40--65 years                                         

  Males:\                   5.9%      2.4%        10.7%   3.0%    22.0%
  40--65 years                                                    

  Females:\                 10.9%     2.9%        7.3%    3.8%    24.9%
  \>65 years                                                      

  Males:\                   11.0%     2.9%        7.7%    3.9%    25.6%
  \>65 years                                                      

  Total                     35.3%     11.8%       38.4%   14.5%   100%
  -----------------------------------------------------------------------

**Abbreviation:** MCT, mobile cardiac telemetry.

###### 

Patients diagnosed with arrhythmia when using MCT, Event, and Holter monitors

           n        Diagnosed   Difference   *P*-value
  -------- -------- ----------- ------------ -----------
  MCT      5,129    61.3%                    
  Event    24,023   23.0%       36%          0.0006
  Holter   57,143   24.2%       35%          0.0006

**Abbreviation:** MCT, mobile cardiac telemetry.

###### 

Patients treated with antiarrhythmic drugs when using MCT, Event, and Holter monitors

           n        Treated   Difference   *P*-value
  -------- -------- --------- ------------ -----------
  MCT      5,005    61.1%                  
  Event    22,078   39.0%     20%          0.0033
  Holter   52,097   43.0%     16%          0.0018

**Abbreviation:** MCT, mobile cardiac telemetry.

###### 

Savings when using MCT: ablation, CABG, heart/pericardium, and valve/septa procedures

                      MCT vs Event   MCT vs Holter                            
  ------------------- -------------- --------------- ---------- -------- ---- ----------
  Ablation            35,114         54              \<0.0001   36,115   45   \<0.0001
  CABG                                                          41,700   32   0.0003
  Heart/pericardium   17,131         43              0.0281     8,606    54   0.0003
  Valve/septa         58,362         35              0.0422     55,390   46   0.0003

**Abbreviations:** MCT, mobile cardiac telemetry; CABG, coronary artery bypass graft; vs, versus.

###### 

Savings (US\$) when using MCT -- ablation

                         Device   Pre-     Post-    Difference   *P*-value
  ---------------------- -------- -------- -------- ------------ -----------
  MCT vs Event (n=54)                                            
   Test                  MCT      16,132   10,376   (5,756)      
   Control               Event    6,043    35,400   29,358       
   Impact                                           (35,114)     \<0.0001
  MCT vs Holter (n=45)                                           
   Test                  MCT      17,996   8,485    (9,511)      
   Control               Holter   2,759    29,362   26,604       
   Impact                                           (36,115)     \<0.0001

**Abbreviations:** MCT, mobile cardiac telemetry; vs, versus.

###### 

Savings (US\$) when using MCT -- CABG

            MCT vs Holter (n=32)                                
  --------- ---------------------- -------- -------- ---------- --------
  Test      MCT                    28,508   17,820   (10,688)   
  Control   Holter                 8,960    39,972   31,012     
  Impact                                             (41,700)   0.0003

**Abbreviations:** MCT, mobile cardiac telemetry; CABG, coronary artery bypass graft; vs, versus.

###### 

Savings (US\$) when using MCT -- heart/pericardium procedures

                         Device   Pre-     Post-    Difference   *P*-value
  ---------------------- -------- -------- -------- ------------ -----------
  MCT vs Event (n=43)                                            
   Test                  MCT      11,227   15,470   4,243        
   Control               Event    2,961    24,334   21,374       
   Impact                                           (17,131)     0.0281
  MCT vs Holter (n=54)                                           
   Test                  MCT      6,010    8,065    2,055        
   Control               Holter   1,016    11,677   10,661       
   Impact                                           (8,606)      0.0003

**Abbreviations:** MCT, mobile cardiac telemetry; vs, versus.

###### 

Savings (US\$) when using MCT -- valve/septa procedures

                         Device   Pre-     Post-     Difference   *P*-value
  ---------------------- -------- -------- --------- ------------ -----------
  MCT vs Event (n=35)                                             
   Test                  MCT      55,624   86,291    30,667       
   Control               Event    23,345   112,374   89,029       
   Impact                                            (58,362)     0.0422
  MCT vs Holter (n=46)                                            
   Test                  MCT      30,429   42,436    12,007       
   Control               Holter   10,912   78,308    67,397       
   Impact                                            (55,390)     0.0003

**Abbreviations:** MCT, mobile cardiac telemetry; vs, versus.
